Schrodinger Inc
SDGR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.18B
Close$
$-23.26
252.7% downside
Current Fair Value
252.7% downsideOvervalued by 252.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.18 Billion |
|---|---|
| Enterprise Value | $1.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 1.64 |
| Outstanding Shares | 73,989,137 |
Return
| Return on Equity | -33.00% |
|---|---|
| Return on Assets | -16.32% |
| Return on Invested Capital | -22.52% |
Valuation & Multiples
| P/E Ratio | -11.27 |
|---|---|
| PEG | -3091.42 |
| Price to Sales | 5.08 |
| Price to Book Ratio | 3.81 |
| Enterprise Value to Revenue | 4.42 |
| Enterprise Value to EBIT | -10.77 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$47.56 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$48.08 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2517▲ 107.11% |
|---|---|
| Total Calls | 456,100▼ 78.06% |
| Total Puts | 570,900▲ 52.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.65%▼ 4.88% |
|---|---|
| Total Invested | $748.36M▼ 39.86% |
| Investors Holding | 237▲ 2.00% |
ESG Score
No data
About Schrodinger Inc
Relevant Senate Committees
Finance
This committee controls Medicare drug pricing, international trade, and tax policy, all of which directly determine the commercial viability of drug pipelines.
Health, Education, Labor, and Pensions
This committee regulates the FDA and NIH, which directly governs the drug approval process and research funding essential to Schrodinger and its partners.
Judiciary
Intellectual property and patent law are the lifeblood of Schrodinger’s business; the committee's oversight of USPTO and antitrust is critical.